Additionally, patients experiencing severe or persistent gastrointestinal side effectsincluding nausea, vomiting, diarrhea, or abdominal painshould not attempt to self-manage these symptoms, as they may indicate pancreatitis, gallbladder disease (right upper quadrant pain, fever, jaundice), or other serious adverse effects requiring immediate evaluation
All authors have read and accepted the final manuscript Authors original submitted files for images Below are the links to the authors original submitted files for images
We covered so much in our time here and just thank you again for coming on the show
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pill, adding to a growing list of competitive threats facing the Danish pharmaceutical giant
Ohya T, Nagai T, Araki Y, Yanagawa T, Tanabe T, Iyoda K, et al